Ozempic (semaglutide) has a US list price of approximately $968 to $1,029 per month as of April 2026, but most uninsured patients do not pay this amount. Through NovoCare Pharmacy and GoodRx’s Novo-backed program, Ozempic is available to eligible cash-pay patients at $349 per month for 0.25mg, 0.5mg, and 1mg doses, or $499 per month for the 2mg dose. New patients may qualify for a $199 introductory price for the first two months. Understanding which savings pathway applies to you — and which do not — is the most important cost decision an uninsured Ozempic patient makes. Advanced TRT Clinic is not affiliated with or endorsed by Novo Nordisk, the manufacturer of Ozempic.
The List Price vs. What You Actually Pay
Ozempic’s list price — approximately $997 per 28-day pen regardless of dose as of mid-2026 — is the number quoted in news articles and pharmacy sticker prices when no discount or insurance is applied. For uninsured patients, this is the starting reference point, but it is not what most patients actually pay.
The gap between list price and actual cash cost has narrowed significantly since late 2025, when Novo Nordisk launched a direct-to-patient cash-pay program through NovoCare Pharmacy. This program, now the most commonly used pathway for uninsured Ozempic patients, sells Ozempic at approximately one-third of list price for eligible cash payers. The most common mistake uninsured patients make in 2026 is using a GoodRx coupon that reflects the retail pharmacy price ($825 to $950 per month) rather than the NovoCare-backed program ($349 per month) — a difference of $500 per month for identical medication.
Ozempic (semaglutide 0.5mg, 1mg, 2mg) is approved for type 2 diabetes and cardiovascular risk reduction in adults with T2D. Wegovy (semaglutide 2.4mg) is the weight management-approved formulation. Cost programs and insurance coverage pathways differ between the two products. This article covers Ozempic costs. Patients without type 2 diabetes who are prescribed semaglutide for weight loss should ask their physician whether Wegovy is the appropriate product for their insurance and clinical situation. Advanced TRT Clinic is not a pharmacy or drug distributor and does not sell or fulfill Ozempic prescriptions.
Complete 2026 Cost Breakdown by Pathway
| Pathway | Monthly Cost | Who Qualifies | Key Restrictions |
|---|---|---|---|
| NovoCare Pharmacy (cash-pay) | $349 (0.5mg, 1mg) $499 (2mg) |
Uninsured or paying out of pocket | No government coverage (Medicare/Medicaid excluded); valid Rx required |
| Introductory offer (new patients) | $199 (first 2 months) | New cash-pay patients at 0.25mg or 0.5mg dose | Verify current availability; offer has been extended multiple times |
| NovoCare Savings Card (insured) | $25 per month | Commercially insured patients only | Does not apply to Medicare, Medicaid, or fully uninsured patients |
| Costco Pharmacy (cash-pay) | $349 (0.5mg, 1mg) $199 first 2 months |
Costco members; same Novo-set pricing as NovoCare | In-person pickup; requires membership; government coverage excluded |
| GoodRx / discount cards (retail) | $825 to $950 | Anyone; free to use | Cannot combine with insurance or NovoCare card; substantially higher than NovoCare direct |
| NovoCare PAP (Patient Assistance) | Free | Uninsured; income at or below 400% FPL (approx. $62,400/year individual) | Application required; 4 to 6 weeks processing; T2D indication required |
| List price (no discount) | $968 to $1,029 | Anyone (no discount applied) | Almost nobody should pay this; always use NovoCare direct or discount card |
GoodRx shows two separate prices for Ozempic: the standard retail coupon price ($825 to $950) and a Novo-backed special offer price ($349). These look similar on the GoodRx interface but differ by approximately $500 per month. If the price starts with an 8 or 9, you are looking at the retail coupon, not the NovoCare-backed offer. Confirm the price and pharmacy before filling — switching pharmacies on the same GoodRx coupon can produce significantly different prices. The NovoCare direct pharmacy and participating pharmacies (including Costco) are the most reliable way to access the $349 price consistently.
The NovoCare Savings Programs Explained
NovoCare cash-pay program (uninsured patients)
The NovoCare cash-pay program is the primary cost reduction pathway for uninsured patients in 2026. It is accessible through NovoCare Pharmacy (novonordisk.com/novocare-pharmacy) or through participating pharmacies including Costco. The eligibility requirement is that the patient must not be covered by any government-funded health insurance program (Medicare Part D, Medicaid, TRICARE, or any other federal or state government program) for the Ozempic prescription being filled. Patients with commercial insurance who prefer to pay out of pocket for privacy or other reasons may also use this program but will not be able to seek reimbursement from their insurer for the out-of-pocket cost.
The $199 introductory price for new patients at starting doses covers the first two fills. This is a particularly useful entry point for patients who are initiating therapy at 0.25mg (the standard 4-week initiation dose) and 0.5mg. Verify current availability of the introductory offer directly with NovoCare, as the end date has been extended multiple times.
NovoCare Savings Card (commercially insured patients)
For patients with commercial insurance (employer-sponsored or individual market plans), the NovoCare Savings Card can reduce monthly copays to as low as $25 per month. This is the most cost-effective pathway for commercially insured patients whose plans cover Ozempic for type 2 diabetes. The card cannot be used with Medicare, Medicaid, or any government-funded program. It cannot be combined with the cash-pay program. Eligibility and copay amounts vary by insurance plan formulary tier.
NovoCare Patient Assistance Program (qualifying low-income patients)
Uninsured patients with household income at or below 400% of the Federal Poverty Level (approximately $62,400 per year for a single individual in 2026) may qualify to receive Ozempic at no cost through the NovoCare Patient Assistance Program (PAP). The application requires physician participation and documentation of income and insurance status. Processing typically takes 4 to 6 weeks. The program requires a valid Ozempic prescription for an FDA-approved indication (primarily type 2 diabetes). Applications can be initiated through NovoCare.com or by calling 1-866-310-7549.
Ozempic Cost With Insurance
For patients with insurance coverage, Ozempic costs are substantially lower. Coverage and copay vary significantly by plan and diagnosis:
Ozempic Cost With Insurance: 2026 Overview
Ozempic vs. Zepbound: Cost Comparison for Weight Management
Patients frequently ask about Ozempic cost in the context of weight management, where semaglutide is sometimes prescribed off-label. For patients whose primary goal is weight loss rather than diabetes management, the cost landscape is different — and tirzepatide (Zepbound) may now be the more cost-effective FDA-approved option.
| Product | Indication | Self-Pay Cost (2026) | Mean Weight Loss |
|---|---|---|---|
| Ozempic 1mg | Type 2 diabetes (off-label for weight loss) | $349/month (NovoCare cash-pay) | Approximately 3 to 6% (subtherapeutic weight loss dose) |
| Wegovy 2.4mg | Weight management (on-label) | Approximately $1,349/month list; varies with savings | 14.9% at 68 weeks (STEP-1) |
| Zepbound (tirzepatide) vials | Weight management (on-label) | $349 to $499/month (Lilly self-pay vials) | 20.2% at 72 weeks (SURMOUNT-5) |
For patients without diabetes seeking weight loss pharmacotherapy who are comparing Ozempic and Zepbound on cost: Zepbound vials at $349 to $499 per month through Eli Lilly’s self-pay program deliver the on-label weight management dose, substantially greater average weight loss (20.2% vs. approximately 5% for Ozempic 1mg off-label), and FDA-verified quality. For uninsured patients whose primary goal is weight loss, the comparison strongly favors Zepbound vials over Ozempic at these self-pay price points. For a full clinical comparison, see our guide on tirzepatide vs. semaglutide: which weight loss injection wins.
Common Cost Mistakes to Avoid in 2026
Ozempic Cost: 4 Mistakes That Cost Patients Money
Does Medicare Cover Ozempic in 2026?
Medicare Part D covers Ozempic for type 2 diabetes under most plans. Since the Inflation Reduction Act’s drug price negotiation provisions took effect, semaglutide is on the list of drugs subject to Medicare price negotiation, which is expected to reduce Part D costs further in coming years. Most Medicare patients with type 2 diabetes pay a copay of $47 to $200 per month depending on their specific Part D plan and formulary tier, and the $2,000 annual out-of-pocket cap introduced for 2025 limits maximum yearly exposure for Part D drugs.
Medicare does not currently cover Ozempic for off-label weight loss without a diabetes diagnosis. Wegovy has Medicare Part D coverage for patients with obesity and established cardiovascular disease following the SELECT trial label expansion, but this applies specifically to Wegovy at 2.4mg, not to Ozempic. Patients who have obesity, no diabetes, and want Medicare coverage for semaglutide should discuss a Wegovy prescription with their physician.
The significant price gap between Ozempic’s list price and cash-pay programs has created a market of fraudulent “discount” vendors, international pharmacy sites, and compounding pharmacies claiming to offer semaglutide at dramatically lower prices. Compounded semaglutide is not legal through standard channels following the FDA’s February 2025 shortage resolution and subsequent enforcement actions. International pharmacy imports are not FDA-regulated. Patients seeking legitimate cost savings should use NovoCare Pharmacy directly (novonordisk.com), Costco Pharmacy, or apply for the PAP program through their physician’s office. Any offer of Ozempic significantly below the $349 cash-pay price without insurance should be approached with significant caution.
Getting a Prescription and Clinical Oversight
Ozempic requires a valid prescription from a licensed physician for an FDA-approved indication (type 2 diabetes, cardiovascular risk reduction in T2D, or chronic kidney disease in T2D). The cost programs described in this article require a legitimate prescription — they do not provide a pathway to obtain the medication without physician evaluation.
Patients considering semaglutide for metabolic health, weight management, or diabetes should begin with a clinical evaluation to establish the appropriate indication and product. For complete guidance on semaglutide dosing, what to expect clinically, and how supervised therapy is structured, see our evidence-based guide on semaglutide for weight management: dosing, risks and expectations.
Get a Clinical Evaluation for GLP-1 Therapy
Advanced TRT Clinic provides physician-supervised metabolic and weight management consultations via telemedicine, including clinical evaluation, medication selection, and ongoing management. We provide evidence-based guidance on treatment options and can help patients navigate prior authorization and savings programme eligibility. Advanced TRT Clinic is not a pharmacy, does not fill prescriptions directly, and is not affiliated with or endorsed by Novo Nordisk or any pharmaceutical manufacturer. Availability varies by state.
